Bevacizumab Shows Potential as First-Line Retinopathy of Prematurity Treatment
While researchers call study results “encouraging,” they note that very low doses may be linked with reactivation.
While researchers call study results “encouraging,” they note that very low doses may be linked with reactivation.
Approximately a quarter of those with diabetic retinopathy at baseline showed improvement.
The study also shows fewer patients with the condition are progressing than prior research indicated.